Anti-viral Actions and Viral Dynamics in the Early Phase of Three Different Regimens of Interferon Treatment for Chronic Hepatitis C: Differences between the Twice-daily Administration of Interferon-beta Treatment and the Combination Therapy with Interferon-alpha Plus Ribavirin

Acta Medica Okayama

Volumn 57, Issue 5, 2003, Pages 217-225

  Nakajima, Hirofumi ^a   Shimomura, Hiroyuki ^a   Iwasaki, Yoshiaki ^a   Ikeda, Fusao ^a   Umeoka, Fumi ^a   Chengyu, Piao ^a   Taniguchi, Hideaki ^a   Ohnishi, Yasuhiro ^a   Takagi, Shin Jirou ^a   Fujioka, Shin Ichi ^a   Shiratori, Yasushi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Antiviral actions; Chronic hepatitis C (CHC); Hepatitis C virus (HCV) dynamics; Interferon (IFN) beta; Real time PCR

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; ALPHA INTERFERON; BETA INTERFERON; DOUBLE STRANDED RIBONUCLEIC ACID DEPENDENT PROTEIN KINASE; PROTEIN; PROTEIN MXA; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; BLOOD CELL; CHRONOSEQUENCE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; DYNAMICS; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; MONONUCLEAR CELL; PATIENT; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RANDOMIZATION; VIRUS INDUCTION; VIRUS LOAD;

2',5'-OLIGOADENYLATE SYNTHETASE; ADULT; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; EIF-2 KINASE; FEMALE; GENE EXPRESSION; GTP-BINDING PROTEINS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERFERON-BETA; KINETICS; MALE; MIDDLE AGED; MONOCYTES; RIBAVIRIN; RNA, VIRAL; TIME FACTORS;

HEPATITIS C VIRUS;

EID: 10744229234     PISSN: 0386300X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA and Margolis HS: The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med (1999) 341: 556-62.
2. El-Serag HB and Mason AC: Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med (1999) 340: 745-50.
3. Samuel CE: Antiviral actions of interferons. Clin Microbiol Rev (2001) 14: 778-809.
4. Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M, Waggoner JG, Park Y, and Jones EA: Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med (1986) 315: 1575-1578.
5. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P and Zarski JP: Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration. Hepatology (1996) 24: 778-89.
6. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C and Albrecht J: Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet (1998) 352: 1426-32.
7. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, O'Grady J, Reichen J, Diago M, Lin A, Hoffman J and Brunda MJ: Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med (2000) 343: 1666-72.
8. Kobayashi Y, Watanabe S, Konishi M, Yokoi M, Kakehashi R, Kaito M, Kondo M, Hayashi Y, Jomori T and Suzuki S: Quantitation and typing of serum hepatitis C virus RNA in patients with chronic hepatitis C treated with interferon-beta. Hepatology (1993) 18: 1319-25.
9. Okushin H, Morii K, Kishi F and Yuasa S: Efficacy of the combination therapy using twice-a-day IFN-beta followed by IFN alpha-2b in treatment for chronic hepatitis C. Acta Hepatolog JPN (1997) 38: 11-18 (in Japanese).
10. Furusyo N, Hayashi J, Ohmiya M, Sawayama Y, Kawakami Y, Ariyama Y, Kinukawa N and Kashiwagi S: Differences between interferon-α and β treatment for patients with chronic hepatitis C virus infection. Dig Dis Sci (1999) 44: 608-617.
11. Shiratori Y, Perelson AS, Weinberger L, Imazeki F, Yokosuka O, Nakata R, Ihori M, Hirota K, Ono N, Kuroda H, Motojima T, Nishigaki M and Omata M: Different turnover rate of hepatitis C virus clearance by different treatment regimen using interferon-beta. J Hepatol (2000) 33: 313-22.
12. Asahina Y, Izumi N, Uchihara M, Noguchi O, Tsuchiya K, Hamano K, Kanazawa N, Itakura J, Miyake S and Sakai T: A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alpha plus ribavirin and intravenous twice-daily treatment with interferon beta. Hepatology (2001) 34: 377-384.
13. Ikeda F, Shimomura H, Miyake M, Fujioka SI, Itoh M, Takahashi A, Iwasaki Y, Sakaguchi K, Yamamoto K, Higashi T and Tsuji T: Early clearance of circulating hepatitis C virus enhanced by induction therapy with twice-a-day intravenous injection of IFN-beta. J Interferon Cytokine Res (2000) 20: 831-836.
14. Ikeda F, Shimomura H, Nakagawa H, Iwasaki Y, Miyake M, Tsuji H, Fujioka S, Itoh M, Takahashi A and Tsuji T: Efficient enhancement of priming effect by intermittent treatment with interferon. Biochem Biophys Res Commun (2000) 278: 599-603.
15. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ and Perelson AS: Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science (1998) 282: 103-107.
16. Zeuzem S, Herrmann E, Lee JH, Fricke J, Neumann AU, Modi M, Colucci G and Roth WK: Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon-a. Gastroenterology (2001) 120: 1438-1447.
17. Herrmann E, Neumann AU, Schmidt JM and Zeuzem S: Hepatitis C virus kinetics. Antivir Ther (2000) 5: 85-90.
18. Staeheli P: Interfron-induced proteins and the antiviral state. Adv Virus Res (1990) 38: 147-200.
19. Der SD and Lau AS: Involvement of the double-stranded-RNA-dependent kinase PKR in interferon expression and interferon-mediated antiviral activity. Proc Natl Acad Sci USA (1995) 92: 8841-8845.
20. Samuel CE: Mechanisms of the antiviral action of interferons. Prog Nucleic Acid Res Mol Biol (1988) 35: 27-72.
21. Okamoto H, Sugiyama Y, Okada S, Kurai K, Akahane Y, Sugai Y, Tanaka T, Sato K, Tsuda F, Miyakawa Y and Mayumi M: Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol (1992) 73: 673-679.
22. Ichida F, Tsuji T, Omata M, Ichida T, Inoue K, Kamimura T, Yamada G, Hino K, Yokosuka O and Suzuki H.: New Inuyama Classification: new criteria for histological assessment of chronic hepatitis. Int Hepatol Commun (1996) 6: 112-119.
23. Boyum A: Isolation of mononuclear cells and granulocytes from human blood. Isolation of mononuclear cells by one centrifugation, and of granulocytes by combination centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl (1968) 97: 77-89.
24. Chomczynski P and Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem (1987) 162: 156-159.
25. Platanias LC, Uddin S and Colamonici OR: Tyrosine phosphrylation of the alpha and beta subunits of the type I interferon receptor. Interferon-beta selectively induces tyrosine phosphorylation of an alpha subunit-associated protein. J Biol Chem (1994) 269: 17761-17764.
26. Hino K, Kondo T, YasudaK, Fukuhara A, Fujioka S, Shioda K, Niwa H, Iino S and Suzuki H: Pharmacokinetics and biological effect of beta interferon by intravenous (iv) bolus administration in healthy volunteer as compared with iv infusion. Jpn J Clin Pharmacol Ther (1988) 19: 625-635 (in Japanese).
27. Lau AS, Hannigan GE, Freedman MH and Williams BR: Regulation of interferon receptor expression in human blood lymphocytes in vitro and during interferon therapy. J Clin Invest (1986) 77: 1632-1638.
28. Khakoo S, Glue P, Grellier L, Wells B, Bell A, Dash C, Murray-Lyon I, Lypnyj D, Flannery B, Walters K and Dusheiko GM: Ribavirin and interferon alpha-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamics interaction. Br J Clin Pharmacol (1998) 46: 563-570.
29. Radaeva S, Jaruga B, Hong F, Kim WH, Fan S, Cai H, Strom S, Liu Y, El-assal O and Gao B: Interferon-α activates multiple STAT signals and down-regulates c-Met in primary human hepatocytes. Gastroenterology (2002) 122: 1020-1034.
30. Solinas A, Cossu P, Poddighe P, Tocco A, Deplano A, Garrucciu G and Diana MS: Change of serum 2′, 5′-oligoadenylate synthetase activity during interferon treatment of chonic hepatits C. Liver (1993) 13: 253-258.
31. Murashima S, Kumashiro R, Ide T, Miyajima I, Hino T, Koga Y, Ishii K, Ueno T, Sakisaka S and Sata M: Effect of interferon treatment on serum 2′, 5′-oligoadenylate synthetase levels in hepatitis C-infected patients. J Med Virol (2000) 62: 185-190.
32. Fernandez M, Quiroga JA, Martin J, Herrero M, Pardo M, Horisberger MA and Carreno V: In vivo and in vitro induction of MxA protein in peripheral blood mononuclear cells from patients chronically infected with hepatitis C virus. J Infect Dis (1999) 180: 262-267.
33. Pawlotsky JM, Hovanessian AG, Roudot-Thoraval F, Robert N, Boubier N, Babany G, Duval J and Dhumeaux D: Effect of α-interferon(IFN-α) on 2′-5′ oligoadenylate synthetase activity in peripheral blood mononuclear cells of patients with chronic hepatitis C: relationship to the antiviral effect of IFN-α. Antimicrob Agents Chemother (1996) 40: 320-324.
34. Antonelli G, Simeoni E, Turriziani O, Tesoro R, Radaelli A, Roffi L, Antonelli L, Pistello M and Dianzani F: Correlation of interferon-induced expression of MxA mRNA in peripheral blood mononuclear cells with the response of patients with chronic active hepatitis C to IFN-alpha therapy. J Interferon Cytokine Res (1999) 19: 243-251.